99 related articles for article (PubMed ID: 11077487)
1. Pancreatic cancer--new aspects of molecular biology research.
Kleeff J; Friess H; Berberat PO; Martignoni ME; Z'graggen K; Büchler MW
Swiss Surg; 2000; 6(5):231-4. PubMed ID: 11077487
[TBL] [Abstract][Full Text] [Related]
2. Growth factors and their receptors in pancreatic cancer.
Ozawa F; Friess H; Tempia-Caliera A; Kleeff J; Büchler MW
Teratog Carcinog Mutagen; 2001; 21(1):27-44. PubMed ID: 11135319
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: factors regulating tumor development, maintenance and metastasis.
Shi X; Friess H; Kleeff J; Ozawa F; Büchler MW
Pancreatology; 2001; 1(5):517-24. PubMed ID: 12120231
[TBL] [Abstract][Full Text] [Related]
4. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
7. Molecular aspects of pancreatic cancer and future perspectives.
Friess H; Kleeff J; Korc M; Büchler MW
Dig Surg; 1999; 16(4):281-90. PubMed ID: 10449972
[TBL] [Abstract][Full Text] [Related]
8. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
10. [Metastasis of pancreatic tumors].
Häberle L; Braren R; Schlitter AM; Esposito I
Pathologe; 2015 Nov; 36 Suppl 2():176-80. PubMed ID: 26391249
[TBL] [Abstract][Full Text] [Related]
11. The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.
Shen R; Wang Q; Cheng S; Liu T; Jiang H; Zhu J; Wu Y; Wang L
Cancer Lett; 2013 Oct; 339(1):135-43. PubMed ID: 23887057
[TBL] [Abstract][Full Text] [Related]
12. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
Li C; Zhao Z; Zhou Z; Liu R
Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
14. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway.
Zhu Z; Xu Y; Zhao J; Liu Q; Feng W; Fan J; Wang P
Br J Cancer; 2015 Apr; 112(8):1367-75. PubMed ID: 25867271
[TBL] [Abstract][Full Text] [Related]
15. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of molecular alterations in human pancreatic carcinoma--an immunohistological study.
Gansauge F; Gansauge S; Schmidt E; Müller J; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):152-5. PubMed ID: 9641888
[TBL] [Abstract][Full Text] [Related]
17. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
Chang W; Liu M; Xu J; Fu H; Zhou B; Yuan T; Chen P
Tumour Biol; 2016 Nov; 37(11):14813-14824. PubMed ID: 27638830
[TBL] [Abstract][Full Text] [Related]
18. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
20. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma.
You N; Li J; Gong Z; Huang X; Wang W; Wang L; Wu K; Zheng L
Mol Carcinog; 2017 Feb; 56(2):607-624. PubMed ID: 27350032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]